Trial Profile
A Phase 1, Blinded, Randomized, Placebo-controlled, Nested Ascending Single Oral Dose and Ascending Multiple Oral Dose Study (with Food Study) to Evaluate Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of MYK-224 in Healthy Volunteers
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2021
Price :
$35
*
At a glance
- Drugs MYK 224 (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Adverse reactions; First in man
- Sponsors MyoKardia
- 04 Aug 2020 Status changed from suspended to recruiting according to a MyoKardia media release.
- 06 May 2020 Status changed from recruiting to suspended in response to the coronavirus pandemic, according to a MyoKardia media release.
- 21 Aug 2019 Status changed from planning to recruiting, according to a MyoKardia media release.